Investigators discovered a more than twofold increase in cases of acute HIV during the COVID-19 pandemic as part of an ED-based screening program at UChicago Medicine. The cause of the increase remains unknown, but it underscores the importance of screening despite the fact the pandemic has strained all resources.
In this registry-based screening study of women in Catalonia, Spain, a negative human papillomavirus (HPV) and cytology co-test at baseline was associated with a cumulative incidence of cervical precancer of 0.4% at five years and 1.3% at nine years, compared to 27% among women with abnormal HPV testing at baseline.
Screening standards for cervical cancer have changed over the past two decades, including several updates since the first consensus guidelines, published in 2001 by the American Society of Colposcopy and Cervical Pathology. The 2020 revision is based on data showing that patients’ risk of developing cervical precancer or cancer can be estimated using screening test results, biopsy results, and consideration of personal patient factors.
In this retrospective cohort study of 1,901 pregnant women between 11 weeks and 13 weeks six days of gestation who had a nuchal translucency (NT) screening for fetal aneuploidies and demonstrated NT measurements > 95th percentile, 47% of fetuses (894/1,901) had an NT between the 95th and 99th percentile and 53% (1,007/1,901) had an NT ≥ the 99th percentile. In addition, of the 43% of fetuses (814/1,901) with at least one abnormality (structural or genetic), 34% (279/814) would have been missed in the first trimester if only cell-free deoxyribonucleic acid was used for prenatal genetic screening.